Compare PLSE & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLSE | IDYA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2015 | 2019 |
| Metric | PLSE | IDYA |
|---|---|---|
| Price | $52.77 | $37.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $22.00 | ★ $52.86 |
| AVG Volume (30 Days) | 531.6K | ★ 663.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | $201.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $12.56 | $24.24 |
| 52 Week High | $58.90 | $42.68 |
| Indicator | PLSE | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 67.23 | 43.85 |
| Support Level | $24.27 | $35.11 |
| Resistance Level | N/A | $37.82 |
| Average True Range (ATR) | 3.85 | 1.27 |
| MACD | -0.21 | -0.40 |
| Stochastic Oscillator | 63.42 | 3.63 |
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.